Brief: Scpharmaceuticals Inc. Announces Positive Top-Line Results From Freedom-Hf Study

Scpharmaceuticals

13/07/2021 21:16

July 13 (Reuters) - scPharmaceuticals Inc  SCPH.O :
    * SCPHARMACEUTICALS INC. ANNOUNCES POSITIVE TOP-LINE RESULTS
FROM
FREEDOM-HF STUDY
    * SCPHARMACEUTICALS - STUDY HALTED EARLY DUE TO HIGHLY
STATISTICALLY SIGNIFICANT REDUCTION IN 30-DAY HEART
FAILURE-RELATED COSTS IN PRESPECIFIED INTERIM ANALYSIS
    * SCPHARMACEUTICALS - REDUCED AVERAGE 30-DAY HEART FAILURE
RELATED
COSTS BY $17,753 PER STUDY SUBJECT IN FUROSCIX VERSUS
HISTORICALLY MATCHED COMPARATORS
    * SCPHARMACEUTICALS INC - NO SERIOUS ADVERSE EVENTS RELATED
TO
FUROSCIX WERE OBSERVED

Source text for Eikon:  ID:nGNX9cTYv2 
Further company coverage:  SCPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))